BMY BMY ブリストル・マイヤ―ズ スクイブ

 BMYのチャート


 BMYの企業情報

symbol BMY
会社名 Bristol-Myers Squibb Co. (BMY ブリストル・マイヤ―ズ スクイブ)
分野(sector)   
産業(industry)   
業種 医薬品   医療関連(Health Care)
概要 事業概要 ブリストル・マイヤーズ・スクイブ(Bristol-Myers Squibb Company)はバイオ医薬品の発見・開発・ライセンス供与・生産・マーケティング流通・販売に従事するバイオ医薬品会社である。同社の医薬品製品は化学合成薬物、または小分子、生物製剤と呼ばれる生物学的プロセスから製造された製品を含む。小分子薬物は丸剤または錠剤の形態で経口投与される。生物製剤は注射または注入によって患者に投与される。同社の製品にはエムプリシティ、オピボ、スピリセル、ヤルボイ、エリクイス、オレンシア、バラクルード、C型肝炎フランチャイズ、レイヤタズフランチャイズ、サスティバフランチャイズを含む。同社はヒト免疫不全ウイルス(HIV)感染を含むウイルス学、腫瘍学; 免疫科学、心臓血管等の治療クラスの製品を提供する。同社の製品は世界中の卸売業者、小売薬局、病院、政府機関、医療従事者に販売される。  ブリストル・マイヤ―ズ・スクイブは米国大手の生物医薬品メ―カ―。主要製品は抗血小板剤「プラビックス」、高血圧・糖尿病性腎症治療薬「アバプロ」、HIV治療薬「レイアタッツ」、B型肝炎治療薬「バラクル―ド」、骨髄性白血病治療薬「スプリセル」、抗精神薬「エビリファイ」、大腸がん治療薬「ア―ビタックス」など。米国、欧州、メキシコ、日本、中国で製造。  Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases.
本社所在地 430 E. 29th Street 14th Floor New York NY 10016 USA
代表者氏名 Giovanni Caforio
代表者役職名 Chairman of the Board Chief Executive Officer
電話番号 +1 212-546-4000
設立年月日 1887年
市場名 NYSE(ニューヨーク証券取引所)
ipoyear
従業員数 23300人
url www.bms.com
nasdaq_url
adr_tso
EBITDA EBITDA(百万ドル) 8583.00000
終値(lastsale)
時価総額(marketcap)
時価総額 時価総額(百万ドル) 77894.97000
売上高 売上高(百万ドル) 22561.00000
企業価値(EV) 企業価値(EV)(百万ドル) 76359.97000
当期純利益 当期純利益(百万ドル) 4976.00000
決算概要 決算概要 BRIEF: For the fiscal year ended 31 December 2018 Bristol-Myers Squibb Co revenues increased 9% to $22.56B. Net income before extraordinary items increased 27% to $4.98B. Revenues reflect United States segment increase of 11% to $12.59B Europe segment increase of 13% to $5.66B. Net income benefited from Site exit costs and other decrease of 79% to $79M (expense) Other Non Rec.

 BMYのテクニカル分析


 BMYのニュース

   2 Biotech Stocks That Could Soar in the Third Quarter  2022/07/02 09:41:00 The Motley Fool
Bristol Myers Squibb and Bluebird Bio have drugs in their pipelines that could soon earn FDA approval.
   Attention Biotech Investors: Mark Your Calendar For These July PDUFA Dates  2022/07/01 09:26:22 Benzinga
The biotech sector is poised to end June on a positive note, despite largely disappointing regulatory decisions scheduled during the month, thanks to a reversal in broader market sentiment. Only one new molecular entity (NME) has been approved thus far in June. NMEs are a key measure of drug innovation as they contain active ingredients yet to be approved by the Food and Drug Administration (FDA). Alnylam Pharmaceutical Inc''s (NASDAQ: ALNY ) RNAi therapeutic Vutrisiran received approval for treating polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults. Acer Therapeutics Inc (NASDAQ: ACER ) and partner Relief Therapeutics Holding AG (OTC: RLFTF ) received a complete response letter for their urea cycle disorder drug . Bristol-Myers Squibb Co (NYSE: BMY ) received approval for its supplemental biologics license application (sBLA) for Breyanzi for large B-cell lymphoma, while it withdrew its application for Reblozyl as a treatment option for anemia in adults with non-transfusion dependent beta-thalassemia.
   Bristol-Myers Squibb Company (NYSE:BMY) Slides -0.22 Percent In Recent Trade, What Can We Expect Next?  2022/06/29 18:00:00 Stocks Register
Bristol-Myers Squibb Company (NYSE:BMY) traded at $78.53 at last check on Wednesday, June 29, made a downward move of -0.22% on its previous day’s price. Looking at the stock we see that its previous close was $78.70 and the beta (5Y monthly) reads 0.54 with the day’s price range being $78.49 – $80.40. The company … Bristol-Myers Squibb Company (NYSE:BMY) Slides -0.22 Percent In Recent Trade, What Can We Expect Next? Read More »
   5 S&P 500 Stocks Ready to Break Out  2022/06/29 15:50:08 InvestorPlace
These S&P 500 stocks are primed to blast through resistance, meaning massive gains for investors. Alphabet ( GOOGL , GOOG ): Anticipation of July’s 20-for-1 stock split should drive this tech titan back into an uptrend. Eli Lilly ( LLY ): Shares are up 17% this year, trouncing the S&P 500. Bristol Myers Squibb ( BMY ): Forget waiting, this stock just blasted a six-year resistance level, jumping to a new record. International Business Machine ( IBM ): Relative strength has this sleepy dividend stock on the brink of breaking through three-year resistance. Domino’s Pizza ( DPZ ): A freshly completed bottoming pattern will send shares of this pizza chain through $400. Last week’s rally ushered many S&P 500 stocks into critical resistance levels, and some even mustered the strength to blast through them. In scanning the large-capitalization stocks of the land, I found five that deserve special attention. And their relative strength suggests more upside to come. Trading around support or resistance thresholds allows traders to play when the odds are in their favor and when there’s an asymmetric payout.
   Bristol-Myers Squibb Stock: When Will The Correction End?  2022/06/29 14:20:58 Seeking Alpha
Bristol-Myers Squibb''s EBITDA margin is 47.2% at the end of Q1, one of the largest in the pharmaceutical industry. Find out when the correction might end.
   Attention Biotech Investors: Mark Your Calendar For These July PDUFA Dates  2022/07/01 09:26:22 Benzinga
The biotech sector is poised to end June on a positive note, despite largely disappointing regulatory decisions scheduled during the month, thanks to a reversal in broader market sentiment. Only one new molecular entity (NME) has been approved thus far in June. NMEs are a key measure of drug innovation as they contain active ingredients yet to be approved by the Food and Drug Administration (FDA). Alnylam Pharmaceutical Inc''s (NASDAQ: ALNY ) RNAi therapeutic Vutrisiran received approval for treating polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults. Acer Therapeutics Inc (NASDAQ: ACER ) and partner Relief Therapeutics Holding AG (OTC: RLFTF ) received a complete response letter for their urea cycle disorder drug . Bristol-Myers Squibb Co (NYSE: BMY ) received approval for its supplemental biologics license application (sBLA) for Breyanzi for large B-cell lymphoma, while it withdrew its application for Reblozyl as a treatment option for anemia in adults with non-transfusion dependent beta-thalassemia.
   Bristol-Myers Squibb Company (NYSE:BMY) Slides -0.22 Percent In Recent Trade, What Can We Expect Next?  2022/06/29 18:00:00 Stocks Register
Bristol-Myers Squibb Company (NYSE:BMY) traded at $78.53 at last check on Wednesday, June 29, made a downward move of -0.22% on its previous day’s price. Looking at the stock we see that its previous close was $78.70 and the beta (5Y monthly) reads 0.54 with the day’s price range being $78.49 – $80.40. The company … Bristol-Myers Squibb Company (NYSE:BMY) Slides -0.22 Percent In Recent Trade, What Can We Expect Next? Read More »
   5 S&P 500 Stocks Ready to Break Out  2022/06/29 15:50:08 InvestorPlace
These S&P 500 stocks are primed to blast through resistance, meaning massive gains for investors. Alphabet ( GOOGL , GOOG ): Anticipation of July’s 20-for-1 stock split should drive this tech titan back into an uptrend. Eli Lilly ( LLY ): Shares are up 17% this year, trouncing the S&P 500. Bristol Myers Squibb ( BMY ): Forget waiting, this stock just blasted a six-year resistance level, jumping to a new record. International Business Machine ( IBM ): Relative strength has this sleepy dividend stock on the brink of breaking through three-year resistance. Domino’s Pizza ( DPZ ): A freshly completed bottoming pattern will send shares of this pizza chain through $400. Last week’s rally ushered many S&P 500 stocks into critical resistance levels, and some even mustered the strength to blast through them. In scanning the large-capitalization stocks of the land, I found five that deserve special attention. And their relative strength suggests more upside to come. Trading around support or resistance thresholds allows traders to play when the odds are in their favor and when there’s an asymmetric payout.
   Bristol-Myers Squibb Stock: When Will The Correction End?  2022/06/29 14:20:58 Seeking Alpha
Bristol-Myers Squibb''s EBITDA margin is 47.2% at the end of Q1, one of the largest in the pharmaceutical industry. Find out when the correction might end.
   Looking Into Bristol-Myers Squibb''s Recent Short Interest  2022/06/29 13:04:30 Benzinga
Bristol-Myers Squibb''s (NYSE: BMY ) short percent of float has risen 4.49% since its last report. The company recently reported that it has 34.46 million shares sold short , which is 1.63% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.3 days to cover their short positions on average. Why Short Interest Matters Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price … Full story available on Benzinga.com
   Global Bone Marrow Transplant Market to Surpass US$ 14,172.21 Million by 2030 - Coherent Market Insights  2022/06/08 17:30:00 Benzinga
SEATTLE , June 8, 2022 /PRNewswire/ -- According to Coherent Market Insights , the global bone marrow transplant market is estimated to be valued at US$ 10,356.1 million in 2022 and is expected to exhibit a CAGR of 4.0% during the forecast period (2022-2030). Key Trends and Analysis of the Global Bone Marrow Transplant Market: Increasing efforts by researchers to develop a drug to prevent complications after undergoing bone marrow transplant is expected to drive the market growth over the forecast period. For instance, in December 2021 , the U.S. Food and Drug Administration approved Abatacept, a drug to prevent acute graft-versus-host disease (GVHD), a life-threatening complication in which T cells in the transplanted donor bone marrow attacks the recipient''s healthy cells and tissues, thereby causing major damage to the liver, skin, and GI tract after hematopoietic stem cell transplant. The FDA approval was based on results from two studies in patients undergoing stem cell transplant.
   Advanced Cervical Cancer Clinical Trial Pipeline Analysis Research Report 2022 by DelveInsight  2022/06/08 17:00:00 Benzinga
New York, USA, June 08, 2022 (GLOBE NEWSWIRE) -- Advanced Cervical Cancer Clinical Trial Pipeline Analysis Research Report 2022 by DelveInsight As per DelveInsight, recent advances in Cervical Cancer have provided new options for treating patients with advanced forms of the disease, fulfilling a significant unmet medical need. Advanced Cervical Cancer Pipeline involves 75+ key companies continuously working towards developing 75+ Advanced Cervical Cancer treatment therapies. DelveInsight''s '' Advanced Cervical Cancer Pipeline Insight 2022 '' report provides comprehensive global coverage of available, marketed, and pipeline Advanced Cervical Cancer therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Advanced Cervical Cancer pipeline domain. Key Takeaways from the Advanced Cervical Cancer Pipeline Report DelveInsight''s Advanced Cervical Cancer Pipeline report depicts a robust space with 75+ active players working to develop 75+ pipeline therapies for Advanced Cervical Cancer treatment.
   SELLAS Life Sciences''s Galinpepimut/Opdivo Combo Shows Increased Survival In Mesothelioma Patients  2022/06/08 16:03:00 Benzinga
SELLAS Life Sciences Group Inc (NASDAQ: SLS ) announced updated data from a Phase 1 clinical trial of galinpepimut-S (GPS), combined with Bristol-Myers Squibb Co''s (NYSE: BMY ) nivolumab (Opdivo) in with malignant pleural mesothelioma (MPM). The trial included patients who were either refractory or relapsed after at least one line of the standard of care therapy. Data from eight patients enrolled in … Full story available on Benzinga.com
   Sellas'' GPS, Opdivo combo shows promise in early stage study in type of lung cancer  2022/06/08 13:48:15 Seeking Alpha
Sellas Life Sciences (SLS) said updated data from a phase 1 trial of its drug galinpepimut-S ((GPS)) in combination with Bristol-Myers Squibb''s (BMY) Opdivo suggested increased…
   French AI biotech startup Owkin gets $80-million shot from Bristol Myers Squibb to accelerate drug development  2022/06/08 10:26:00 Tech.Eu
Owkin will use the investment to support its data generation strategy in multiple therapeutic areas with a strong focus on multimodal and rich biological data

 関連キーワード  (医薬品 米国株 BMY ブリストル・マイヤ―ズ スクイブ BMY )

 twitter  (公式ツイッターやCEOツイッターなど)

BMY動画